Does Rallies show Form 4 insider transactions for FENC?

Yes. Rallies tracks FENC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FENC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FENC. It does not provide personalized investment advice.

FENC (Fennec Pharmaceuticals Inc. Common Stock) Stock Analysis - Insider Trades

Fennec Pharmaceuticals Inc. Common Stock (FENC) is a publicly traded Healthcare sector company. As of May 21, 2026, FENC trades at $9.69 with a market cap of $333.48M and a P/E ratio of -28.41. FENC moved +0.00% today. Year to date, FENC is +30.00%; over the trailing twelve months it is +19.34%. Its 52-week range spans $3.96 to $10.27. Analyst consensus is strong buy with an average price target of $14.67. Rallies surfaces FENC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FENC stock inside the company?

Recent FENC insider activity includes Raykov Rosty sold 10.95K, Raykov Rosty sold 10.08K, Raykov Rosty sold 10.35K, Raykov Rosty sold 10.31K, and Southpoint Capital Advisors LP sold 1.00M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FENC Key Metrics

Key financial metrics for FENC
Metric	Value
Price	$9.69
Market Cap	$333.48M
P/E Ratio	-28.41
EPS	$-0.34
Dividend Yield	0.00%
52-Week High	$10.27
52-Week Low	$3.96
Volume	5.24K
Avg Volume	0
Revenue (TTM)	$44.64M
Net Income	$-9.74M
Gross Margin	0.00%

Recent FENC Insider Trades

Raykov Rosty sold 10.95K (~$69.07K) on Apr 1, 2026.
Raykov Rosty sold 10.08K (~$84.26K) on Mar 2, 2026.
Raykov Rosty sold 10.35K (~$80.31K) on Feb 2, 2026.
Raykov Rosty sold 10.31K (~$78.37K) on Jan 2, 2026.
Southpoint Capital Advisors LP sold 1.00M (~$7.50M) on Dec 24, 2025.

Latest FENC News

Fennec to Present Four PEDMARK Otoprotection Studies at ASCO 2026 — Apr 21, 2026
Fennec Launches Phase I/II PEDMARK Trial in AYA Head and Neck, Testicular Cancers — Apr 7, 2026
Fennec Posts 50% FY Sales Growth, 75% Q4 Increase and $42M Raise — Mar 24, 2026
Adherex Q4 EPS Seen at $0.03; Revenue to Jump 88.8% — Mar 5, 2026
Fennec Launches PEDMARK® Real-World Study at Tampa General to Reduce Cisplatin Ototoxicity — Mar 4, 2026

FENC Analyst Consensus

4 analysts cover FENC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.67.

Common questions about FENC

Who is trading FENC stock inside the company?: Recent FENC insider activity includes Raykov Rosty sold 10.95K, Raykov Rosty sold 10.08K, Raykov Rosty sold 10.35K, Raykov Rosty sold 10.31K, and Southpoint Capital Advisors LP sold 1.00M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FENC?: Yes. Rallies tracks FENC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FENC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FENC. It does not provide personalized investment advice.